Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results

BACKGROUND: Hypofractionated stereotactic radiotherapy (hFSRT) is a salvage option for recurrent glioblastoma (GB) which may synergize anti-PDL1 treatment. This phase I study evaluated the safety and the recommended phase II dose of anti-PDL1 durvalumab combined with hFSRT in patients with recurrent...

Descripción completa

Detalles Bibliográficos
Autores principales: Pouessel, Damien, Ken, Soléakhéna, Gouaze-Andersson, Valérie, Piram, Lucie, Mervoyer, Augustin, Larrieu-Ciron, Delphine, Cabarrou, Bastien, Lusque, Amélie, Robert, Marie, Frenel, Jean-Sebastien, Uro-Coste, Emmanuelle, Olivier, Pascale, Mounier, Muriel, Sabatini, Umberto, Sanchez, Eduardo Hugo, Zouitine, Mehdi, Berjaoui, Ahmad, Cohen-Jonathan Moyal, Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485381/
https://www.ncbi.nlm.nih.gov/pubmed/37196069
http://dx.doi.org/10.1093/oncolo/oyad095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485381/
https://www.ncbi.nlm.nih.gov/pubmed/37196069
http://dx.doi.org/10.1093/oncolo/oyad095

Ejemplares similares